Bay Colony Advisory Group Inc d b a Bay Colony Advisors Buys Shares of 7,696 Revvity, Inc. (NYSE:RVTY)

Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Revvity, Inc. (NYSE:RVTY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 7,696 shares of the company's stock, valued at approximately $983,000.

Several other institutional investors also recently bought and sold shares of RVTY. EdgePoint Investment Group Inc. bought a new position in Revvity during the second quarter valued at about $209,221,000. Jane Street Group LLC raised its holdings in Revvity by 516.4% during the first quarter. Jane Street Group LLC now owns 453,343 shares of the company's stock valued at $47,601,000 after buying an additional 379,802 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Revvity by 18.5% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,126,271 shares of the company's stock valued at $223,258,000 after buying an additional 332,632 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Revvity by 3.9% in the first quarter. Janus Henderson Group PLC now owns 5,664,528 shares of the company's stock worth $594,769,000 after purchasing an additional 210,100 shares during the period. Finally, Coronation Fund Managers Ltd. increased its stake in shares of Revvity by 261.3% in the first quarter. Coronation Fund Managers Ltd. now owns 253,722 shares of the company's stock worth $26,641,000 after purchasing an additional 183,490 shares during the period. 86.65% of the stock is currently owned by institutional investors.

Revvity Price Performance

NYSE RVTY traded up $1.16 during trading on Monday, reaching $117.49. 772,396 shares of the company traded hands, compared to its average volume of 815,058. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. The stock's 50 day moving average price is $121.51 and its two-hundred day moving average price is $113.55. The company has a market cap of $14.50 billion, a price-to-earnings ratio of 97.10, a P/E/G ratio of 3.27 and a beta of 1.05. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $128.15.

Revvity (NYSE:RVTY - Get Free Report) last released its quarterly earnings data on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.10. The company had revenue of $691.70 million for the quarter, compared to the consensus estimate of $690.33 million. Revvity had a return on equity of 7.34% and a net margin of 6.26%. The company's quarterly revenue was down 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $1.21 earnings per share. As a group, analysts anticipate that Revvity, Inc. will post 4.75 EPS for the current year.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity's payout ratio is 23.14%.

Insider Buying and Selling at Revvity

In other news, insider Joel S. Goldberg sold 3,500 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total value of $412,510.00. Following the transaction, the insider now directly owns 33,400 shares of the company's stock, valued at $3,936,524. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Tajinder S. Vohra sold 2,154 shares of the business's stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at $2,392,237.96. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Joel S. Goldberg sold 3,500 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total transaction of $412,510.00. Following the completion of the transaction, the insider now owns 33,400 shares of the company's stock, valued at $3,936,524. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 7,807 shares of company stock valued at $937,576. 0.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RVTY. Jefferies Financial Group lifted their price objective on Revvity from $115.00 to $125.00 and gave the stock a "hold" rating in a research note on Monday, July 29th. Wells Fargo & Company began coverage on Revvity in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $130.00 price objective on the stock. Leerink Partnrs upgraded Revvity to a "strong-buy" rating in a research note on Monday, July 8th. Citigroup lifted their price objective on Revvity from $135.00 to $145.00 and gave the stock a "buy" rating in a research note on Tuesday, July 30th. Finally, Leerink Partners lifted their price objective on Revvity from $130.00 to $135.00 and gave the stock an "outperform" rating in a research note on Thursday, October 17th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $127.20.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.